Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound are expected to transition to the ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The recall, according to a news release published Wednesday, involves Northwest Naturals' Feline Turkey Recipe raw frozen pet ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...